Endocrine Abstracts

The aim of the study was to assess the effectiveness of postmenopausal osteoporosis (PMOP) therapy with denosumab.Patients and methods 32 postmenopausal women with established PMOP for a period of 24 months or more received denosumab 60 mg subcutaneously once every 6 months combined with calcium and vitamin D. A quantitative assessment of bone mineral density (BMD) was carried out before treatment, after 12 and 24 months of observation, using dual-energy X-ray absorptiometry o...